See more : Enertopia Corp. (ENRT) Income Statement Analysis – Financial Results
Complete financial analysis of Microba Life Sciences Limited (MAP.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Microba Life Sciences Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- BitFuFu Inc. (FUFU) Income Statement Analysis – Financial Results
- Amincor, Inc. (AMNCB) Income Statement Analysis – Financial Results
- Aesthetic Medical International Holdings Group Limited (PAIYY) Income Statement Analysis – Financial Results
- JBB Builders International Limited (1903.HK) Income Statement Analysis – Financial Results
- Made Tech Group Plc (MTEC.L) Income Statement Analysis – Financial Results
Microba Life Sciences Limited (MAP.AX)
About Microba Life Sciences Limited
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 12.09M | 5.42M | 4.69M | 3.73M | 2.91M | 1.83M |
| Cost of Revenue | 20.67M | 12.19M | 2.32M | 9.04M | 6.96M | 4.32M |
| Gross Profit | -8.58M | -6.77M | 2.37M | -5.30M | -4.05M | -2.49M |
| Gross Profit Ratio | -70.99% | -124.96% | 50.46% | -142.12% | -139.32% | -136.21% |
| Research & Development | 10.84M | 9.34M | 5.38M | 1.54M | 163.27K | 0.00 |
| General & Administrative | 12.18M | 7.81M | 8.57M | 821.98K | 1.98M | 1.10M |
| Selling & Marketing | 786.35K | 692.71K | 540.71K | 338.22K | 224.71K | 317.85K |
| SG&A | 12.97M | 4.12M | 9.11M | 2.73M | 3.19M | 2.30M |
| Other Expenses | -17.90M | 3.08K | 4.82M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.91M | 13.45M | 18.64M | 4.27M | 3.35M | 2.30M |
| Cost & Expenses | 38.88M | 25.65M | 20.96M | 13.30M | 10.32M | 6.62M |
| Interest Income | 1.00M | 878.05K | 49.55K | 101.71K | 101.58K | 68.30K |
| Interest Expense | 69.22K | 60.41K | 8.31K | 23.46K | 36.97K | 24.03K |
| Depreciation & Amortization | 2.87M | 1.64M | 1.54M | 1.22M | 1.09M | 765.18K |
| EBITDA | -17.10M | -17.07M | -9.86M | -6.28M | -5.53M | -4.02M |
| EBITDA Ratio | -141.45% | -342.89% | -211.36% | -223.78% | -217.09% | -220.11% |
| Operating Income | -26.84M | -20.23M | -11.45M | -9.57M | -7.41M | -4.79M |
| Operating Income Ratio | -222.02% | -373.18% | -244.27% | -256.41% | -254.59% | -261.96% |
| Total Other Income/Expenses | 6.85M | 1.46M | 4.81M | 2.05M | 748.94K | 68.19K |
| Income Before Tax | -19.99M | -18.77M | -11.46M | -7.52M | -6.66M | -4.72M |
| Income Before Tax Ratio | -165.34% | -346.28% | -244.45% | -201.58% | -228.85% | -258.23% |
| Income Tax Expense | -51.30K | -6.09M | 9.23K | 1.00 | -6.52K | 12.97K |
| Net Income | -19.94M | -12.68M | -11.47M | -7.52M | -6.65M | -4.73M |
| Net Income Ratio | -164.92% | -233.95% | -244.64% | -201.58% | -228.62% | -258.94% |
| EPS | -0.05 | -0.04 | -0.04 | -0.03 | -0.02 | -0.02 |
| EPS Diluted | -0.05 | -0.04 | -0.04 | -0.03 | -0.02 | -0.02 |
| Weighted Avg Shares Out | 409.86M | 332.99M | 290.71M | 290.71M | 290.71M | 290.71M |
| Weighted Avg Shares Out (Dil) | 409.86M | 332.99M | 290.71M | 290.71M | 290.71M | 290.71M |
Source: https://incomestatements.info
Category: Stock Reports